Pia Giovannelli has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Filamin A in triple negative breast cancer

    by Pia Giovannelli, Marzia Di Donato, Fabrizio Licitra, Emilia Sabbatino, Viviana Tutino, Gabriella Castoria, Antimo Migliaccio


  • Open Access

    Exosomes: Emerging Modulators of Pancreatic Cancer Drug Resistance

    by Marzia Di Donato, Nicola Medici, Antimo Migliaccio, Gabriella Castoria, Pia Giovannelli

    Pancreatic cancer (PaC) is one of the most lethal tumors worldwide, difficult to diagnose, and with inadequate therapeutical chances. The most used therapy is gemcitabine, alone or in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), and the multidrug FOLFIRINOX. Unfortunately, PaC develops resistance early, thus reducing the already poor life expectancy of patients. The mechanisms responsible for drug resistance are not fully elucidated, and exosomes seem to be actively involved in this phenomenon, thanks to their ability to transfer molecules regulating this process from drug-resistant to drug-sensitive PaC cells. These extracellular vesicles are released by both normal and cancer cells and seem to be essential mediators of intercellular communications, especially in cancer, where they are secreted at very high numbers. This review illustrates the role of exosomes in PaC drug resistance. This manuscript first provides an overview of the pharmacological approaches used in PaC and, in the last part, focuses on the mechanisms exploited by the exosomes released by cancer cells to induce drug resistance.


  • Faculty Opinions recommendation of The androgen receptor in bladder cancer.

    by Ferdinando Auricchio, Pia Giovannelli, Marzia Di Donato

    Epidemiological evidence suggests that the frequency of bladder cancer is higher in men than in women. Preclinical and clinical findings support the possibility that, more than the androgen receptor (AR) expression level, it is the circulating androgens that are responsible for the increased bladder cancer incidence in males. In particular, the androgen-AR axis could contribute to bladder cancer progression and metastasis through stimulation of cancer cell proliferation, migration, and invasiveness. The signaling pathways responsible for these biological processes can also be activated by non-steroid ligands such as EGF and ILs. Different aspects of this review should be underlined: - the presence of a membrane AR, which could be responsible for bladder cancer progression in the absence of nuclear AR through activation of non-genomic pathways. - the presence of AR in immune cells (CD8+T) that kill cancer cells. The steroid receptor impairs the anti-tumor activity of immune cells, as previously proposed in various cancers such as prostate cancer and melanoma. - targeting AR in bladder cancers, particularly in those resistant to chemotherapy and immunotherapy with BCG, could strongly increase the efficacy of therapies, thus reducing cancer mortality.

  • Open Access

    Role of the Androgen Receptor in Gender-Related Cancers

    by Emilia Sabbatino, Viviana Tutino, Fabrizio Licitra, Marzia Di Donato, Gabriella Castoria, Antimo Migliaccio, Pia Giovannelli

    The androgen receptor (AR) is expressed in many cell types, and its related signaling is widely investigated in hormone-dependent cancers such as prostate and breast. The significance of the AR, however, has been detected even in other cancers, including gastric, bladder, kidney, lung, hepatic, and pancreatic, in which growth and spreading are not strictly or notoriously dependent on sex steroid hormone action. The incidence and mortality of these cancers are, however, somewhat related to gender and, specifically, are higher in men than in women, with the ratio reaching 3–4:1 for bladder cancer. This direct correlation between cancer incidence, mortality, and gender makes sex one of the most important risk factors for these cancers and has incited investigation about the role of sex steroid receptors and their activating hormones in gender-related cancers. In these cancers, the AR is often expressed and seems to play a pivotal role in different processes contributing to cancer onset and progression such as growth, spreading, and epithelial to mesenchymal transition (EMT). This manuscript will offer an overview of the role of the AR in many cancers of the respiratory and gastrointestinal systems wherein its role has been at least partially analyzed. Understanding the role of the AR in these tumors could help us to identify a new biomarker for early diagnostic guidance and to develop better therapeutic approaches by directly targeting the AR or its downstream signaling in individual cells of hormone-related cancers at different stages.


  • Open Access

    The Androgen Regulation of Matrix Metalloproteases in Prostate Cancer and Its Related Tumor Microenvironment

    by Carmela Sorrentino, Rosa D’angiolo, Giulia Gentile, Pia Giovannelli, Bruno Perillo, Antimo Migliaccio, Gabriella Castoria, Marzia Di Donato

    Prostate cancer represents the most common type of cancer among males and the second leading cause of cancer death in men in Western society. In most cases (~70%), PC has a slow and symptom-free growth, whereas it is more aggressive in the remaining patients. Current PC therapies prevalently target the proliferative function of the androgen receptor and may only be effective within short periods, beyond which the disease will progress to metastatic and castration-resistant phenotype. Preclinical and clinical studies are aimed at investigating the molecular basis for prostate cancer spreading. Although considerable efforts have been made to dissect the programs that foster prostate cancer spreading, few biomarkers predictive of metastatic phenotype have yet been identified and few therapeutic options are available for treatment of the metastatic disease. In the present paper, we will discuss innovative aspects of prostate cancer biology, which impinge on the role of cancer-associated fibroblasts and the released matrix metalloproteinases in the disease progression. Investigating these aspects might allow the discovery of clinically actionable biomarkers to target in the advanced stages of prostate cancer.


  • Open Access

    The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue

    by Marzia Di Donato, Pia Giovannelli, Antimo Migliaccio, Gabriella Castoria

    Prostate cancer (PC) represents the most diagnosed and the second most lethal cancer in men worldwide. Its development and progression occur in concert with alterations in the surrounding tumor microenvironment (TME), made up of stromal cells and extracellular matrix (ECM) that dynamically interact with epithelial PC cells affecting their growth and invasiveness. PC cells, in turn, can functionally sculpt the TME through the secretion of various factors, including neurotrophins. Among them, the nerve growth factor (NGF) that is released by both epithelial PC cells and carcinoma-associated fibroblasts (CAFs) triggers the activation of various intracellular signaling cascades, thereby promoting the acquisition of a metastatic phenotype. After many years of investigation, it is indeed well established that aberrations and/or derangement of NGF signaling are involved not only in neurological disorders, but also in the pathogenesis of human proliferative diseases, including PC. Another key feature of cancer progression is the nerve outgrowth in TME and the concept of nerve dependence related to perineural invasion is currently emerging. NGF released by cancer cells can be a driver of tumor neurogenesis and nerves infiltrated in TME release neurotransmitters, which might stimulate the growth and sustainment of tumor cells.In this review, we aim to provide a snapshot of NGF action in the interactions between TME, nerves and PC cells. Understanding the molecular basis of this dialogue might expand the arsenal of therapeutic strategies against this widespread disease.


  • Open Access

    The Role of the Androgen Receptor in Skeletal Muscle and Its Utility as a Target for Restoring Muscle Functions

    by Carmela Sorrentino, Giulia Gentile, Rosa D’angiolo, Carmela Barra, Ferdinando De Stefano, Fabrizio Licitra, Emilia Sabbatino, Viviana Tutino, Antimo Moretti, Pia Giovannelli, et al.

    Aging is accompanied by a progressive decrease in skeletal muscle mass and function. This process is characterized by the decrease of sex steroid hormone levels due to andropause and menopause. The axis androgens/androgen receptor (AR) sustains muscle size through classic (also called genomic) and non-classic (or non-genomic) actions to elicit various biological responses. Non-genomic androgen effects act through the crosstalk of AR with other partners. Recently, a specific interaction has been shown to occur through AR and filamin A or Src in different types of normal and malignant cells. From these interactions, the activation of several downstream effectors (paxillin, FAK, MAPK, Akt) follows. Such events induce cell proliferation and survival as well as metabolic changes. Irrespective of the sex of the individual, the more important signaling hubs linking the AR non-genomic circuit with cytoskeleton organization have been analyzed by the Western blot of lysate proteins from human skeletal muscle biopsies (obtained from both young and old patients) and C2C12 skeletal muscle cells. The phosphorylation of filamin A and paxillin increases in biopsies derived from old patients (>61 years), as compared with those derived from young patients (<58 years). Furthermore, AR is weakly expressed in samples from old patients, as compared with young patients. Consistent with these findings, C2C12 cells express abundant amounts of AR that increase during the differentiation. This latter finding suggests an involvement of the androgen-triggered rapid activation of several signaling effectors (e.g., MAPK, Akt, Src, FAK) in skeletal muscle disease. Taken together, our findings suggest that the downregulation of the androgen signaling, or of the AR expression, is a key node in the pathogenesis of skeletal muscle related to aging, and is thus related to excessive metabolic functions and loss of skeletal muscle. Given the important knowledge gaps with regards to the mechanism by which androgens regulate skeletal mass functions, more research is needed. Other in vitro or in vivo experiments are necessary in order to inform the utility of targeting the non-genomic AR signaling pathways with new selective androgen receptor modulators and to improve the clinical outcome of age-related frailty and sarcopenia.


  • Open Access

    New Approaches Targeting the Invasive Phenotype of Prostate Cancer-Associated Fibroblasts

    by Marzia Di Donato, Pia Giovannelli, Antimo Migliaccio, Gabriella Castoria

    Prostate cancer (PC) is one of the most widespread malignancies among males worldwide. The androgen receptor (AR) drives its development and progression and still represents the main target of PC therapy. Second-generation antiandrogens have, indeed, improved the patient’s management. Nonetheless, hormone resistance and tumour progression frequently develop. While the majority of drugs currently used in PC target the AR functions in epithelial PC cells, the role of the receptor in PC-associated fibroblasts (CAFs) and PC progression remains unresolved, and only a few therapeutics affecting the stromal AR functions have been developed so far. By combining several approaches, we have shown that AR associates with Filamin A (FLNa), thus promoting migration and invasion of androgen-challenged CAFs from PC patient’s specimens at different Gleason’s scores. By using 2D and 3D cultures, we have demonstrated that CAFs move towards epithelial PC cells and promote the increase in PC organoid size. The stapled peptide Rh-2025u disrupts the androgen-triggered AR/FLNa complex assembly and impairs these responses in monolayer cells as well as 3D models. Furthermore, it reduces the overall tumour area in androgen-treated 3D co-culture. Mechanistically, our findings posit that AR/FLNa complex recruits β1 integrin and the membrane type-matrix metalloproteinase 1 upon the androgen challenging of CAFs. The activation of a protease cascade leading to extracellular matrix (ECM) remodelling then follows. Rh-2025u peptide interferes in the assembly of this multimolecular complex and impairs ECM remodelling. As such, CAFs can no longer navigate through ECM. In summary, we propose the Rh-2025u peptide as a new drug, which alone or in combination with other emerging therapies may allow a more rational treatment of PC. Pharmacological blockade of AR functions in CAFs is indeed neglected and the approach we propose would improve the treatment’s outcome in PC patients.


  • Open Access

    Agri-Food By-Products in Cancer: New Targets and Strategies

    by Carmela Sorrentino, Martina Di Gisi, Giulia Gentile, Fabrizio Licitra, Rosa D’angiolo, Pia Giovannelli, Antimo Migliaccio, Gabriella Castoria, Marzia Di Donato

    The globalization and the changes in consumer lifestyles are forcing us to face a deep transformation in food demand and in the organization of the entire food production system. In this new era, the food-loss and food-waste security nexus is relevant in the global debate and avoiding unsustainable waste in agri-food systems as well as the supply chain is a big challenge. “Food waste” is useful for the recovery of its valuable components, thus it can assume the connotation of a “food by-product”. Sustainable utilization of agri-food waste by-products provides a great opportunity. Increasing evidence shows that agri-food by-products are a source of different bioactive molecules that lower the inflammatory state and, hence, the aggressiveness of several proliferative diseases. This review aims to summarize the effects of agri-food by-products derivatives, already recognized as promising therapeutics in human diseases, including different cancer types, such as breast, prostate, and colorectal cancer. Here, we examine products modulating or interfering in the signaling mediated by the epidermal growth factor receptor.